Thermo Fisher launches assays to identify SARS-CoV-2 mutations

March 11, 2021

Thermo Fisher Scientific launched its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations, according to a news release.

The company said the assays – which are available for research use only – enable surveillance of variants that are causing COVID-19 infections in specific regions globally and allow laboratories to choose which mutations to track.

The TaqMan SARS-CoV-2 Mutation Panel is designed to be highly scalable, being able to run a few or hundreds of samples to identify one or many mutations. The panel provides laboratories with the ability to meet various levels of testing need with real-time PCR instruments they already use, the company said.  

The TaqMan SARS-CoV-2 Mutation Panel provides results in about an hour and is based on gold standard TaqMan SNP genotyping assay technology, which can help to detect and distinguish mutations efficiently.

Visit Thermo Fisher Scientific for more news